Psoriatic arthritis: Strategies for challenging cases. Case report

Cover Page

Cite item

Full Text

Abstract

This clinical case demonstrates a severe, highly active form of psoriatic arthritis with pronounced peripheral arthritis, dactylitis, enthesitis, and widespread skin lesions. The patient had radiographically confirmed signs of sacroiliitis, spondylitis, and significant structural changes (stage III–IV according to the Steinbrocker classification). The course of the disease was complicated by multiple comorbid conditions, including metabolic syndrome with morbid obesity (BMI 46 kg/m²), hyperuricemia, and subsequently clinically established diabetes insipidus. An additional factor that significantly limited the effectiveness of treatment was the patient's low adherence to therapy and repeated refusals to undergo the recommended examinations by related specialists. There was marked resistance of the disease to both the maximum tolerable doses of basic anti-inflammatory drugs and various groups of genetically engineered biological therapies. Despite repeated attempts to optimise treatment, it was not possible to achieve sustained control of the disease: only partial effectiveness of therapy was recorded, accompanied by periodic exacerbations and persistent high activity of the pathological process.

About the authors

Alida K. Karibova

City Clinical Hospital, Makhachkala

Author for correspondence.
Email: solomon687@gmail.com
ORCID iD: 0009-0003-3690-3041

Department Head

Russian Federation, Makhachkala

Magomed T. Kudaev

Dagestan State Medical University

Email: solomon687@gmail.com
ORCID iD: 0000-0001-5446-1775

D. Sci. (Med.), Prof.

Russian Federation, Makhachkala

References

  1. Lubrano E, Scriffignano S, Perrotta FM. Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis. Rheumatol Ther. 2023;10(5):1119-25. doi: 10.1007/s40744-023-00574-w
  2. Ayan G, Ribeiro A, Macit B, Proft F. Pharmacologic Treatment Strategies in Psoriatic Arthritis. Clin Ther. 2023;45(9):826-40. doi: 10.1016/j.clinthera.2023.05.010
  3. Panagiotopoulos A, Fragoulis GE. Comorbidities in Psoriatic Arthritis: A Narrative Review. Clin Ther. 2023;45(2):177-89. doi: 10.1016/j.clinthera.2023.01.006
  4. Salikhova DI, Golovicheva VV, Fatkhudinov TK, et al. Therapeutic Efficiency of Proteins Secreted by Glial Progenitor Cells in a Rat Model of Traumatic Brain Injury. Int J Mol Sci. 2023;24(15):12341. doi: 10.3390/ijms241512341
  5. Azuaga AB, Ramírez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci. 2023;24(5):4901. doi: 10.3390/ijms24054901
  6. Артамонова О.Г., Карамова А.Э., Кубанов А.А., и др. Поиск прогностических маркеров псориатического артрита у больных псориазом. Вестник дерматологии и венерологии. 2023;99(5):41-51 [Artamonova OG, Karamova AE, Kubanov AA, et al. Search for predictors of psoriatic arthritis in patients with psoriasis. Vestnik dermatologii i venerologii. 2023;99(5):41-51 (in Russian)]. doi: 10.25208/vdv14871
  7. Kalyoncu U, Bayindir Ö, Ferhat Öksüz M, et al. The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford). 2017;56(2):279-86. doi: 10.1093/rheumatology/kew375
  8. Polachek A, Al-Johani R, Li S, et al. Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. Semin Arthritis Rheum. 2019;48(5):834-9. doi: 10.1016/j.semarthrit.2018.08.005
  9. Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022;18(6):311-25. doi: 10.1038/s41584-022-00776-6
  10. Gossec L, McGonagle D, Korotaeva T, et al. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. J Rheumatol. 2018;45(1):6-13. doi: 10.3899/jrheum.170449
  11. Lubrano E, Scriffignano S, Azuaga AB, et al. Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatol Ther. 2020;7(4):825-36. doi: 10.1007/s40744-020-00229-0
  12. Braña I, Loredo M, Pardo E, et al. Patients With Psoriatic Arthritis-Related Enthesitis and Persistence on Tofacitinib Under Real-World Conditions. J Rheumatol. 2024;51(7):682-8. doi: 10.3899/jrheum.2024-0016
  13. Логинова Е.Ю., Коротаева Т.В., Губарь Е.Е., и др. Трудный для лечения (difficult-to-treat) псориатический артрит. Данные Общероссийского регистра пациентов с псориатическим артритом. Современная ревматология. 2024;18(5):16-21 [Loginova EY, Korotaeva TV, Gubar EE, et al. Difficult-to-treat psoriatic arthritis. Data from the All-Russian registry of patients with psoriatic arthritis. Modern Rheumatology Journal. 2024;18(5):16-21 (in Russian)]. doi: 10.14412/1996-7012-2024-5-16-21
  14. Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706-19. doi: 10.1136/ard-2024-225531
  15. Корсакова Ю.Л., Коротаева Т.В., Эрдес Ш.Ф., и др. Обновленные международные рекомендации (EULAR, 2023) по лечению псориатического артрита. Научно-практическая ревматология. 2024;62(5):474-83 [Korsakova YL, Korotaeva TV, Erdes S, et al. Updated international recommendations (EULAR, 2023) for the treatment of psoriatic arthritis. Rheumatology Science and Practice. 2024;62(5):474-83 (in Russian)]. doi: 10.47360/1995-4484-2024-474-483

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Karibova A.K., Kudaeva M.T. Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).